^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CIML NK

    i
    Other names: CIML NK
    Associations

    News

    Trials
    Company:
    Dana-Farber Cancer Institute
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=15, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Proleukin (aldesleukin) • CIML NK
    9ms
    CIML NK Cells With Venetoclax for AML (clinicaltrials.gov)
    P1, N=10, Recruiting, Dana-Farber Cancer Institute | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Proleukin (aldesleukin) • CIML NK
    9ms
    A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Dana-Farber Cancer Institute | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • CIML NK
    10ms
    First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer. (PubMed, J Hematol Oncol)
    CIML NK cells combined with N-803 and ipilimumab to treat head and neck cancer is safe, and associated with a more proliferative NK cell phenotype. However, the combination leads to reduced HLA mismatched NK cell persistence, resulting in an important limitation affecting NK cell combination therapies in clinical trials. These results inform evaluation of CIML NK therapy for advanced malignancies, with considerations for combination with IPI.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    12ms
    A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=50, Enrolling by invitation, Dana-Farber Cancer Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • CIML NK
    12ms
    CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov)
    P1, N=11, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases • Immune cell
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    1year
    Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CIML NK
    1year
    Memory-like Natural Killer (NK) Cell Therapy in Patients with Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=5, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CIML NK
    1year
    CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | N=25 --> 11
    Enrollment closed • Enrollment change • Combination therapy • Metastases • Immune cell
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    over1year
    Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=5, Not yet recruiting, Dana-Farber Cancer Institute | Initiation date: Jun 2024 --> Sep 2024 | Trial primary completion date: Feb 2025 --> Dec 2025
    Trial initiation date • Trial primary completion date • Combination therapy
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK
    over1year
    CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. (PubMed, Sci Adv)
    CAR arming of the CIML NK cells subtanstially reduced their dysfunction in patient-derived ascites fluid with transcriptomic changes related to altered metabolism and tonic signaling as potential mechanisms. Lastly, the adoptive transfer of MSLN-CAR CIML NK cells demonstrated remarkable inhibition of tumor growth and prevented metastatic spread in xenograft mice, supporting their potential as an effective therapeutic strategy in EOC.
    Journal
    |
    MSLN (Mesothelin)
    |
    CIML NK
    over1year
    CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases • Immune cell
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • CIML NK